Identification of Chimeric NTRK3 Genes in Papillary Thyroid Cancer Cells by Analyzing the Imbalance of the Expression of 5’ and 3’ mRNA Fragments-Reference-Cited by-全球学者库

Identification of Chimeric NTRK3 Genes in Papillary Thyroid Cancer Cells by Analyzing the Imbalance of the Expression of 5’ and 3’ mRNA Fragments

Published:2023-06 Issue:2 Volume:175 Page:239-244
ISSN:0007-4888
Container-title:Bulletin of Experimental Biology and Medicine
language:en
Short-container-title:Bull Exp Biol Med

Author:

Oskorbin I. P.,Ivanov A. A.,Smertina M. A.,Demidova I. A.,Boyarskikh U. A.,Kechin A. A.,Bakharev S. Yu.,Samuilenkova O. V.,Vihlyanov I. V.,Kushlinskii N. E.,Filipenko M. L.

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10517-023-05842-x.pdf

Reference15 articles.

1. Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open. 2016;1(2):e000023. https://doi.org/10.1136/esmoopen-2015-000023

2. Khotskaya YB, Holla VR, Farago AF, Mills Shaw KR, Meric-Bernstam F, Hong DS. Targeting TRK family proteins in cancer. Pharmacol. Ther. 2017;173:58-66. https://doi.org/10.1016/j.pharmthera.2017.02.006

3. Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat. Rev. Clin. Oncol. 2018;15(12):731-747. https://doi.org/10.1038/s41571-018-0113-0

4. Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD; trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21(2):271-282. https://doi.org/10.1016/S1470-2045(19)30691-6

5. Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, van Tilburg CM, Nagasubramanian R, Berlin JD, Federman N, Mascarenhas L, Geoerger B, Dowlati A, Pappo AS, Bielack S, Doz F, McDermott R, Patel JD, Schilder RJ, Tahara M, Pfister SM, Witt O, Ladanyi M, Rudzinski ER, Nanda S, Childs BH, Laetsch TW, Hyman DM, Drilon A. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020;21(4):531-540. https://doi.org/10.1016/S1470-2045(19)30856-3